UA109868C2 - Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) - Google Patents

Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)

Info

Publication number
UA109868C2
UA109868C2 UAA201500428A UAA201500428A UA109868C2 UA 109868 C2 UA109868 C2 UA 109868C2 UA A201500428 A UAA201500428 A UA A201500428A UA A201500428 A UAA201500428 A UA A201500428A UA 109868 C2 UA109868 C2 UA 109868C2
Authority
UA
Ukraine
Prior art keywords
compounds
alkyltriazole
asr
disorders
substituents
Prior art date
Application number
UAA201500428A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Стівен Дімс Гебріель
Метью Майкл Гамільтон
Метью С. Лукас
Імінь Цянь
Ачютарао Сіддурі
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109868(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA109868C2 publication Critical patent/UA109868C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UAA201500428A 2012-06-20 2013-06-17 Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) UA109868C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
UA109868C2 true UA109868C2 (ru) 2015-10-12

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500428A UA109868C2 (ru) 2012-06-20 2013-06-17 Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)

Country Status (22)

Country Link
US (1) US9321738B2 (Direct)
EP (1) EP2864300A1 (Direct)
JP (1) JP2015520202A (Direct)
KR (1) KR20150021057A (Direct)
CN (1) CN104411692A (Direct)
AU (1) AU2013279512A1 (Direct)
BR (1) BR112014030685A2 (Direct)
CA (1) CA2869541A1 (Direct)
CL (1) CL2014003243A1 (Direct)
CO (1) CO7131358A2 (Direct)
CR (1) CR20140525A (Direct)
EA (1) EA201492285A1 (Direct)
HK (1) HK1206342A1 (Direct)
IL (1) IL236088A0 (Direct)
IN (1) IN2014DN09348A (Direct)
MA (1) MA37764A1 (Direct)
MX (1) MX2014014710A (Direct)
PE (1) PE20142448A1 (Direct)
PH (1) PH12014502789A1 (Direct)
SG (1) SG11201407220YA (Direct)
UA (1) UA109868C2 (Direct)
WO (1) WO2013189864A1 (Direct)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003499A2 (pt) 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
BR112014030674A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos n-ariltriazol como antagonistas do lpar
MX382748B (es) 2013-03-15 2025-03-13 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
EP3162801B1 (en) 2014-06-27 2020-07-22 UBE Industries, Ltd. Salt of halogen-substituted heterocyclic compound
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
LT3710438T (lt) * 2017-12-19 2021-12-27 Bristol-Myers Squibb Company Triazolo per n prijungtos karbamoilcikloheksilo rūgštys kaip lpa antagonistai
CN112041302B (zh) 2017-12-19 2024-11-19 百时美施贵宝公司 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
CN111712492B (zh) 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
ES2944304T3 (es) * 2017-12-19 2023-06-20 Bristol Myers Squibb Co Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
CN112041304B (zh) 2017-12-19 2025-03-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸
KR102726939B1 (ko) 2017-12-19 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
ES2942767T3 (es) * 2017-12-19 2023-06-06 Bristol Myers Squibb Co Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
KR102777148B1 (ko) 2017-12-19 2025-03-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
SG11202005807QA (en) * 2017-12-29 2020-07-29 Biomarin Pharm Inc Glycolate oxidase inhibitors for the treatment of disease
KR102800284B1 (ko) * 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
ES2941774T3 (es) 2018-09-18 2023-05-25 Bristol Myers Squibb Co Acidos oxabiciclo como antagonistas de LPA
CN113473985A (zh) * 2018-09-18 2021-10-01 百时美施贵宝公司 作为lpa拮抗剂的环戊酸
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
KR20230019880A (ko) 2020-06-03 2023-02-09 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
TWI818538B (zh) 2021-05-11 2023-10-11 美商基利科學股份有限公司 Ｌｐａ受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
CA3238094A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
EA201390821A1 (ru) * 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
BR112014003499A2 (pt) * 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula

Also Published As

Publication number Publication date
IN2014DN09348A (Direct) 2015-07-17
PH12014502789A1 (en) 2015-02-09
SG11201407220YA (en) 2014-12-30
US20150133511A1 (en) 2015-05-14
KR20150021057A (ko) 2015-02-27
EA201492285A1 (ru) 2015-04-30
CO7131358A2 (es) 2014-12-01
CL2014003243A1 (es) 2015-03-20
JP2015520202A (ja) 2015-07-16
MX2014014710A (es) 2015-03-04
CN104411692A (zh) 2015-03-11
CA2869541A1 (en) 2013-12-27
HK1206342A1 (en) 2016-01-08
BR112014030685A2 (pt) 2017-06-27
PE20142448A1 (es) 2015-01-28
US9321738B2 (en) 2016-04-26
WO2013189864A1 (en) 2013-12-27
EP2864300A1 (en) 2015-04-29
IL236088A0 (en) 2015-02-01
AU2013279512A1 (en) 2014-10-16
MA37764A1 (fr) 2016-01-29
CR20140525A (es) 2015-01-12

Similar Documents

Publication Publication Date Title
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2014DN09352A (Direct)
IN2014DN09347A (Direct)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EP4609866A3 (en) Oxysterols and methods of use thereof
MX2015017964A (es) Inhibidores de bromodominio.
MX2016002794A (es) Compuestos antiproliferativos.
IN2015DN01119A (Direct)
PH12014501991A1 (en) Phenicol antibacterials
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2013040227A3 (en) Therapeutic compounds
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY191352A (en) Aldosterone synthase inhibitors
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase